Literature DB >> 35402132

A case of pulmonary leiomyosarcoma achieving long-term survival after multiple metastasectomies.

Yuki Azumi1, Tomoyuki Wakahara1, Kiyonori Kanemitsu1, Shinobu Tsuchida1, Mitsuru Sasako1, Kyoko Otani2, Takeshi Iwasaki1.   

Abstract

A 58-year-old man who underwent lower lobectomy of the right lung for primary pulmonary leiomyosarcoma (PPL) 4 years ago presented with epigastric pain and was diagnosed with small bowel intussusception caused by an intestinal mass. Partial resection of the small intestine was performed, and pathological examination revealed metastatic leiomyosarcoma. Masses in the left adrenal gland, subcutaneous tissue of the left upper arm, right pleura, jejunum, right trapezius muscle, and right adrenal gland were subsequently detected in the following 4 years. Resection was performed for each tumor, which was histologically confirmed as metastatic leiomyosarcoma. However, 1 month after the last surgery, multiple systemic metastases were found, thus, he is currently undergoing chemotherapy. The patient has been alive for 8 years and 4 months after the first operation for PPL. PPL is an extremely rare disease with no established treatment strategy for recurrences. Aggressive metastasectomy may be beneficial in selected cases.
© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2022.

Entities:  

Keywords:  Metastasectomy; Primary pulmonary leiomyosarcoma; Recurrence

Year:  2022        PMID: 35402132      PMCID: PMC8938522          DOI: 10.1007/s13691-022-00535-0

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  8 in total

1.  Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Winette T A van der Graaf; Jean-Yves Blay; Sant P Chawla; Dong-Wan Kim; Binh Bui-Nguyen; Paolo G Casali; Patrick Schöffski; Massimo Aglietta; Arthur P Staddon; Yasuo Beppu; Axel Le Cesne; Hans Gelderblom; Ian R Judson; Nobuhito Araki; Monia Ouali; Sandrine Marreaud; Rachel Hodge; Mohammed R Dewji; Corneel Coens; George D Demetri; Christopher D Fletcher; Angelo Paolo Dei Tos; Peter Hohenberger
Journal:  Lancet       Date:  2012-05-16       Impact factor: 79.321

2.  Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  P G Casali; N Abecassis; H T Aro; S Bauer; R Biagini; S Bielack; S Bonvalot; I Boukovinas; J V M G Bovee; T Brodowicz; J M Broto; A Buonadonna; E De Álava; A P Dei Tos; X G Del Muro; P Dileo; M Eriksson; A Fedenko; V Ferraresi; A Ferrari; S Ferrari; A M Frezza; S Gasperoni; H Gelderblom; T Gil; G Grignani; A Gronchi; R L Haas; B Hassan; P Hohenberger; R Issels; H Joensuu; R L Jones; I Judson; P Jutte; S Kaal; B Kasper; K Kopeckova; D A Krákorová; A Le Cesne; I Lugowska; O Merimsky; M Montemurro; M A Pantaleo; R Piana; P Picci; S Piperno-Neumann; A L Pousa; P Reichardt; M H Robinson; P Rutkowski; A A Safwat; P Schöffski; S Sleijfer; S Stacchiotti; K Sundby Hall; M Unk; F Van Coevorden; W T A van der Graaf; J Whelan; E Wardelmann; O Zaikova; J Y Blay
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

3.  Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.

Authors:  Ian Judson; Jaap Verweij; Hans Gelderblom; Jörg T Hartmann; Patrick Schöffski; Jean-Yves Blay; J Martijn Kerst; Josef Sufliarsky; Jeremy Whelan; Peter Hohenberger; Anders Krarup-Hansen; Thierry Alcindor; Sandrine Marreaud; Saskia Litière; Catherine Hermans; Cyril Fisher; Pancras C W Hogendoorn; A Paolo dei Tos; Winette T A van der Graaf
Journal:  Lancet Oncol       Date:  2014-03-05       Impact factor: 41.316

4.  Ifosfamide and doxorubicin in the treatment of advanced leiomyosarcoma.

Authors:  Serkan Akin; Omer Dizdar; Yusuf Karakas; Alev Turker; Ayse Kars
Journal:  Curr Probl Cancer       Date:  2018-01-31       Impact factor: 3.187

5.  Soft Tissue Sarcoma, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Margaret von Mehren; R Lor Randall; Robert S Benjamin; Sarah Boles; Marilyn M Bui; Kristen N Ganjoo; Suzanne George; Ricardo J Gonzalez; Martin J Heslin; John M Kane; Vicki Keedy; Edward Kim; Henry Koon; Joel Mayerson; Martin McCarter; Sean V McGarry; Christian Meyer; Zachary S Morris; Richard J O'Donnell; Alberto S Pappo; I Benjamin Paz; Ivy A Petersen; John D Pfeifer; Richard F Riedel; Bernice Ruo; Scott Schuetze; William D Tap; Jeffrey D Wayne; Mary Anne Bergman; Jillian L Scavone
Journal:  J Natl Compr Canc Netw       Date:  2018-05       Impact factor: 11.908

6.  Primary pulmonary leiomyosarcoma: A population-based study.

Authors:  Bao-Dong Qin; Xiao-Dong Jiao; Yuan-Sheng Zang
Journal:  Lung Cancer       Date:  2017-12-29       Impact factor: 5.705

7.  The treatment and outcome of patients with soft tissue sarcomas and synchronous metastases.

Authors:  John M Kane; J William Finley; Deborah Driscoll; William G Kraybill; John F Gibbs
Journal:  Sarcoma       Date:  2002

8.  The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.

Authors:  Tomoki Nakamura; Akihiko Matsumine; Akira Kawai; Nobuhito Araki; Takahiro Goto; Tsukasa Yonemoto; Hideshi Sugiura; Yoshihiro Nishida; Hiroaki Hiraga; Kanya Honoki; Taketoshi Yasuda; Shogen Boku; Akihiro Sudo; Takafumi Ueda
Journal:  Cancer       Date:  2016-03-11       Impact factor: 6.860

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.